PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume contents, Author index and Subject index to Volume 19

L.
9
82

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1984, U.S. $800.00 including postage and insurance, 2 years, 1984/85, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1984 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163-7258/83 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

VO
1
19

Volume 19, 1982, Numbers 1–3

CONTENTS

Number 1

	PAGE
Bordetella pertussis toxins: *A. C. Wardlaw and R. Parton*	1
Toxins of *Staphylococcus aureus*: *J. H. Freer and J. P. Arbuthnott*	55
Diphtheria toxin: *T. Uchida*	107
Thermostable direct hemolysin of *Vibrio parahaemolyticus*: *Y. Takeda*	123

Number 2

Smoking, nicotine and electrocortical activity: *J. A. Edwards and D. M. Warburton*	147
Clostridium botulinum toxins: *G. Sakaguchi*	165
Biochemical aspects of action mechanisms of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) and related chemicals in animals: *F. Matsumura*	195
Mechanisms of fever: *R. Hellon and Y. Townsend*	211
The biology and toxicology of molluscicides, Bayluscide®: *P. Andrews, J. Thyssen and D. Lorke*	245

Number 3

Neurohypophyseal hormones and brain neurochemistry: *D. H. G. Versteeg*	297
Lysosomal storage diseases: *R. O. Brady*	327
Problems of delivery of drugs to the brain: *N. Bodor and M. E. Brewster*	337
Antiviral effects of phosphonoformate (PFA, foscarnet sodium): *B. Öberg*	387
Psychopharmacology of hunger and food intake in humans: *T. Silverstone*	417
Biological response modifiers and their promise in clinical medicine: *A. M. Attallah, J. T. Yeatman, R. P. Johnson and J. C. Petricciani*	435

DL.
19
982

AUTHOR INDEX

Andrews, P. 245
Arbuthnott, J. P. 55
Attallah, A. M. 435

Bodor, N. 337
Brady, R. O. 327
Brewster, M. E. 337

Edwards, J. A. 147

Freer, J. H. 55

Hellon, R. 211

Johnson, R. P. 435

Lorke, D. 245

Matsumura, F. 195

Öberg, B. 387

Parton, R. 1
Petricciani, J. C. 435

Sakaguchi, G.
Silverstone, T. 417

Takeda, T. 123
Thyssen, J. 245
Townsend, Y. 211

Uchida, T. 10 &

Versteeg, D. H. G. 297

Warburton, D. M. 147
Wardlow, A. C. 1

Yeatman, J. T. 435

VOI
19
198

SUBJECT INDEX

Adrenalectomy and *Bordetella pertussis* toxin 18
Adverse drug reaction, phosphonoformate 410
Amitriptyline and hunger 423, 424
Amphetamine
  anorectic action basis 430
  food intake 428, 429
  hunger 419
Anisomysin, effects on fever 232
Arachidonic acid metabolism and fever 230, 231

Bayluside ® *see* niclosamide
B-cell scheme and *Bordetella pertussis* toxin site 26
Behavior, eating and drugs 425–30
Benzodiazepines and hunger 424
Berberine *see also* dihydro
  brain delivery and dihydropyridine–pyridinium salt 363–72
  brain efflux 370
  brain insulin efflux 371
  distribution coefficients 364
  dose–response curve 371
  organ distribution 367, 368
  P388 leukemia effects 372
  partitioning 365
  structure 363
Biomphalaria glabrata
  developmental stages and niclosamide 257
  niclosamide effects 256
Blood–brain barrier
  CSF homeostasis 344
  molecular carriers 339–43
  molecular movement 343–5
  pathological effects 345
  radiation 348
  structure and enzymes 337–9
  transport systems 342
Bordetella pertussis toxins 1–43
  complications 38–40
  heat-labile toxin (HLT) 1
    chemistry 6
    definition 5
    dermonecrotizing activity 7
    immunological properties 6, 7
    production and purification 5, 6
    stability 5
    toxicity 7, 8
  interactions 2, 3
  lipopolysaccharide (LPS) 1
    biological activities 4
    chemistry 3, 4
    features 3
  location 1
  pertussigen
    adipocyte glycerol release 31
    adjuvant 27–9
    antisera neutralization 15
    B-cell scheme 26
    biological acticity 13–15, 30, 31
    epinephrine hyperglycemia 25
    glucose and insulin changes in mice 22, 23
    histamine sensitization 15–18
    islet activation 20–7
    leucocytosis 18–20
    molecular basis of activity 31–4
    molecular weight 11
    nomenclature and definition 8–10
    physicochemical properties 12
    purification and yield 10, 11
    stability 12, 13
    sububits 12
  production in culture 1, 2
  research needs 45, 46
  role in infections 34–40
    man 36–40
    mice 34–6
  types 1
Botulism
  animal 168, 169
  food-borne 167, 168
  human 167, 168
  infant 168
  pathogenesis 167
  wound 168
Brain
  direct drug administration 350, 351
  drug delivery 350–80
  prodrugs 351, 352
Brain injury models 347

Cestodes, niclosamide effects 274, 275
Chalones
  assays 448, 449
  clinical trials 450
  effects 449, 450
  mechanism of action 448
  types 448
Chemical delivery systems 372–80
Chick edema factor 195
Chlorpromazine and hunger 423
Cholecystokinin
  food intake 430
  hunger 421
Chondroitin sulfate 329
Clostridium botulinum toxin *see also* botulism
  activation and structure 180–3
  bacteriophages and production 173
  bioassay 170, 171
  characterization 166
  classification 169, 170
  derivative, molecular structure 179, 180
  intestinal absorption 183, 184
  in vitro assay 171
  LD_{50} and molecular size 183
  mode of action 184–7
  nomenclature 166, 167
  production and growth 171–3
  progenitor, molecular structure 176–9
  purification of progenitors 174–6
    organism groups 175, 176
  types discovery 165, 166
Contingent negative variation (CNV) and smoking 159–61
Cyproheptadine and hunger 422

Dermatan sulfate 329
Diethylpropion and hunger 420
Dihydroberberine
  distribution coefficients 364
  dose–response curve 371

oxidation rate 366
P388 leukemia effects 372
partitioning 365
slow infusion 369
Dihydropyridine–pyridinium salt redox systems, stability 366
Diphthamide structure 110
Diphtheria toxin 107–20
antitoxin immunodiffusion 112
cross-reacting materials 111–13
properties 108
cytotoxicity 116
entry kinetics 115–17
fragments 110, 111
A, cytosol 118, 119
A, membrane passage 117, 118
HeLa cell entry competition 113
production 107, 108
protein synthesis inhibition 108
receptor binding 113–15
Dipsosauris dorsalis, survival and fever prevention 236
DNA polymerases, phosphonoformate effects 390
DNase, phosphonoformate effects 391
Dopamine
chemical delivery system 375–7
structure 375
Drugs
brain delivery 350–81
chemical delivery systems 372–80
food intake 425–30
increasing hunger 422–5
suppressing hunger 417–22
transport systems to brain 342

Elongation factor 2 108
Endotoxin and pyrogen properties 216, 217
Enzyme induction, TCDD effects 197–9
Enzyme replacement trials
lipid storage diseases 329–31
targeting 331–3
Event related potentials (ERP) and smoking 151, 152, 157–9

Fabry's disease 328
Factor thymique serique, features and therapeutic effects 438
Farber's disease 328
Fenfluramine
food intake 429, 430
and hunger 421
Fever 211–38 *see also* pyrogens
anisomysin effects 232, 233
clinical causes 214, 215
experimental studies 216–26
heat elimination and temperature 214
heat exchange in rabbit 212
and hyperthermia 211–14
monoamine mediation 226, 227
neonates 233–6
plasma iron 237, 238
pregnancy 233–6
prostaglandin blockade 230
prostaglandin mediation 227–31
survival in lizards 236, 237
value 236–8
Fish, niclosamide effects 285
Food intake and drugs, measurement methods 425–8
Foscarnet sodium *see* phosphonoformate
Fucosidosis 328

Gangliosides, *Vibrio parahaemolyticus* infection 138, 140, 141
Gangliosidosis 328
Gaucher's disease 328
Glucocerebroside, trimannosyldilysine 332
Glycoproteins
carbohydrate structure 331
deglycosylation 332
hexose cleavage 332

Heparan sulfate 329
Hepatic encephalopathy 349
Herpes infection and phosphonoformate 403
cutaneous 402, 404, 405
genital 405
keratitis 406
strains 405, 406
systemic 407
Hunger
assessment 417, 418
drug effects 417–25
Hypertension 346
encephalopathy 346, 347
Hyperthermia, fever distinction 211–14
Inhibitory effects, phosphonoformate on enzymes 389
Insulin and hunger 424
Interferon
antitumor effects 444, 445
antiviral effects 444
applications 446, 447
assay 446
classes 443
production mechanisms 443, 444
purification 445, 446
Interleukins 442, 443
Invertebrates, niclosamide effects 266, 269

Keratan sulfate 329
Krabbe's disease 328

Lithium and hunger 424, 425
Lymphotoxin
assays 441, 442
features 441
mechanism of action 442
Lysosomal storage disease 327–34
enzyme defects 328
enzyme replacement trials 329–31
enzyme targeting 331–3
signs and accumulated lipids 328
therapy and CNS 333, 334

Mazindol and hunger 420
Memory and brain monoamines 303
Metachromatic leucodystrophy 328
1-Methyl-3,5-*bis*(*N*-β-phenylethyl-carbamoyl-1,4-dihydropyridine, brain oxidation 375
N-Methylpyridinium-2-carbaldoxime chloride (and pro-2PAM)
acetylcholinesterase reactivation 357
blood concentration and formulation 355–7
brain delivery 352–63
distribution and time 358
efflux from organs 359–62
heat of formation 354
structure 352
Methysergide and hunger 423
Monoamines and fever 226, 227

Naloxone and food intake 430
Neurophyseal hormones 297–319
amino acid sequences 298
analogs and fragments 317–19
history 297

Niclosamide and ethanolamine salt (active ingredient of Bayluscide ®)
adsorption 264, 265
amphibia effects 267, 270
analysis 249, 250
aquatic invertebrates 266–9
bioassay 251, 252
biodegradation 265, 266
cestocidic effects 271, 272, 274, 275
chlorine effects 263
effects on snails 254, 255
embryotoxicity 280, 281
fate 273, 276, 282
fish 284, 285
formulations 252, 253
livestock 283, 284
mode of action 259–61
mutagenicity 280
pH and effects 261, 262
plants affected 270, 271
resistance 258, 259
risk evaluation 285, 286
snail age and effects 255, 256
snail egg effects 256, 257
solubility 247
stability data 247–9
light 248, 249
structure 245
structure–activity relationship 246, 247
synonyms 246
temperature effects 262, 263
toxicity 273–86
acute 276–8
long-term 279, 280
trematocide 272, 273
vegetation effects 263, 264
water hardness 263
Nicotine
central neurophysiology 149, 150
nervous system distribution 147, 148
neurochemical action 148–50
peripheral neurophysiology 149
Niemann–Pick disease 328

Oxytocin
amino acid sequences 298
brain catecholamines 308, 309
brain 5-HT 309

Pasteurella multocida, growth and temperature 238
Pertussigen *see Bordetella pertussis*
Pertussis vaccine
features 40
human infant toxicity 43–6
mouse protection 29, 30
toxicity in mice 40–2
X-mode and C-mode adjuvant 28, 29
β-Phenethylamine
chemical delivery system 373–5
structure 373
Phenmetrazine and hunger 419, 420
Phentermine and hunger 420
Phenylpropanolamine and hunger 420, 421
Phosphonoformate
analogs and polymerases 392–4
antiviral effects 387–412
blood half-life 408, 409
cell culture virus multiplication 395
cellular effects 400, 401
clinical studies 409, 410
enzymes inhibited 388–91
esters and virus infection 395
HSV-1 DNA synthesis 398, 399
mechanism of action 396–9
cell culture 399, 400
pharmacokinetics 407, 408
resistance 398
structure 387, 388
structure–activity relations 391
toxicology 408
virus infected animals 401–7 *see also* herpes
virus multiplication 391
Polymerases, pyrophosphate analog effects 392–4
Pregnancy, febrile effects 233–6
Prolyl-leucyl-glycinamide (PLG, MIF-1) 298
brain catecholamines 311–15
neurochemical effects 315, 316
striatal dopamine 314
Prostaglandins and fever mediation 227–31
blockade effects 230
CSF release 228, 229
PGE_1 site of action 228
Pyrogen
activation 218, 219
cells producing 217, 218
circulating 220, 221
discovery 216, 217
dose–response curve 222
hypothalamic neurones 224
neuronal responses 223–5
purification 219, 220
removal, kidney 225, 226
site of action 221–3
synthesis and release 219

Reverse transcripticase, phosphonoformate 388–90
RNase and phosphonoformate effects 390

Sandhoff's diseases 328
Schistosomiasis, compound screening 245
Smoking
brain effects 153–5
contingent negative variation 159–61
electrocortical activity 151–62
electroencephalograms 151, 152
event related potentials 151, 152, 157–9
research methods 152
Snails, species affected by niclosamide 254
Sodium valproate and hunger 425
Sphingolipidoses, features and lesions 328
Sphingosine structure 327
Staphylococcal scalded skin syndrome 83
Staphylococcus aureus toxins 55–97
α-toxin
amino acid analysis 59, 62, 63
biological activities 62, 64–6
characteristics 60, 61
description 56
erythrocyte interactions 65, 66
isoelectric point 59
isolated membrane interactions 64
membrane lesions 62, 64
molecular weight 59
production 56–8
purification 58, 59
β-toxin (lysin)
amino acid composition 68, 70
biological properties 72
description 66, 67
enzyme activity 70
hot–cold hemolysis 71, 72
molecular weight 68
production 67
properties 68, 69
purification 67, 68
species sensitivity of erythrocytes 71
stability 68, 70
σ-toxin (lysin)
amino acid composition 76, 78, 79
biological effects *in vivo* 80

characteristics 77
cytolysis 79, 80
description 75
isoelectric point 77
molecular weight 76, 77
production and purification 76
stability 79
enterotoxins
amino acid composition 93
characterization 92, 93
description 89, 90
cross reactions 94
detection 90, 91
food poisoning 90
genetic control 92
mode of action 94, 95
physicochemical properties 92
production 91, 92
epidermolytic toxins
amino acids 86
discovery 83
genetic control 87, 88
mode of action 88, 89
production assay 85, 87
γ-toxin (lysin)
ceil damage 74 , 75
description 72, 73
enzyme activity 74
in vivo effects 75
production 73
purification 73, 74
leucocidin
description 80, 81
membrane interactions 82, 83
production and purification 81
properties 81, 82
toxic shock syndrome 95–7
types 55

Tay–Sachs disease 328
TCDD (2, 3, 7, 8-tetrachlorodibenzo-*p*-dioxin) 195–206
aryl hydrocarbon hydroxylase induction 197, 198
ATPase effects, liver membranes 201
elimination rates 200
membrane effects 203, 204
membrane electrophoresis 202
poisoning symptoms 196, 197
significance 204–6
species effects 200
toxic mechanisms 199, 200
Vietnam 195
Testosterone
chemical delivery systems 377-81
-17-nicotinate-*N*-methyl cation in blood and brain 381
structure 379
Thermoregulation *see* fever, hyperthermia
Thymic hormones, biological effects 435–40
Thymic humeral factor, features and applications 439
Thymopoietins 439, 440
Thymosin
applications 437, 438
biochemistry 436, 437
Toxic shock syndrome 95–7
Toxins *see also* organisms producing
Bordetella pertussis 1–46
cholera 42
Clostridium botulinum 165–87
diphtheria 107–20
Pseudomonas aeruginosa 109
Staphylococcus aureus 55–97
typhoid 42
Vibrio parahaemolyticus 123–44
Transfer factor
mechanism of action 441
preparation 440, 441
properties and assays 440

Vaccine, pertussis 28–30
Vasopressin
amino acid sequences 298
brain catecholamines 298–301
brain 5-HT 306, 307
catecholamine modulation 300
des-glycinamide, neurochemical effects 317
memory 303
microinjection studies 303–6
neurochemical effects 307
neuromodulation effects 301–3
passive avoidance behaviour 304
Vasotocin
amino acid sequences 298
brain 5-HT 316, 317
Vibrio parahaemolyticus 123–44
antihemolysin titers 143
blood pressure 142
clinical signs of infection 139–44
diarrhea 141
electrocardiograms 142, 143
Elek test 124
enteropathogenicity 123, 124
first isolation 123
food poisoning symptoms 141
thermostable direct hemolysin (TDH)
amino acid composition 128
cardiotoxicity 134–9
cardiotoxicity and gangliosides 138, 140, 141
clinical signs 139–44
cytotoxicity and FL cells 129–31
disc gel electrophoresis 127
enterotoxicity and FL cells 132–4
hemolysis 129
heat stability 126, 128, 129
isolation 124, 125
lethal toxicity 134
membrane receptor 139
properties 126, 127
purification 125, 126
Virus *see also* herpes
inhibition by phosphonoformate 395
mechanism of phosphonoformate inhibition 396–9

L.
9
82